甘氨双唑钠同步放化疗治疗食管癌的疗效

Efficacy of concurrent chemoradiotherapy with glycididazole sodium in the treatment of esophageal cancer

目的探讨甘氨双唑钠(CM-Na)同步放化疗治疗食管癌的疗效。方法122例食管癌患者,应用计算机数字随机排序的方式分为对照组和研究组,每组61例。对照组患者采用常规同步放化疗,研究组患者则在对照组基础上联合使用CM-Na化疗。比较两组患者治疗效果、不良反应发生率、生存率。结果研究组治疗总有效率86.89%高于对照组的72.13%,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(χ^2=1.151,P=0.283)。研究组患者治疗后1、3、5年的生存率分别为93.44%(57/61)、73.77%(45/61)、52.46%(32/61),对照组患者治疗后1、3、5年的生存率分别为88.52%(54/61)、55.74%(34/61)、32.79%(20/61)。两组患者治疗后1年生存率比较,差异无统计学意义(χ^2=0.899,P>0.05)。研究组患者治疗3、5年后生存率高于对照组,差异均具有统计学意义(χ^2=4.346、4.826,P<0.05)。结论通过应用CM-Na同步放化疗治疗食管癌能在保证安全的前提下进一步提高治疗效果以及远期生存率。

Objective To discuss the therapeutic effect of concurrent chemoradiotherapy with glycididazole sodium(CM-Na)in the treatment of esophageal cancer.Methods A total of 122 patients with esophageal cancer were divided into control group and research group according to computer random method,with 61 cases in each group.The control group was treated with conventional concurrent chemoradiotherapy,and the research group was treated with CM-Na chemotherapy based on the control group.The therapeutic effect,incidence of adverse reactions and survival rate were compared between the two groups.Results The total effective rate of treatment 86.89%of the research group was higher than 72.13%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(χ^2=1.151,P=0.283).After 1,3 and 5 years of treatment,the survival rate of the research group were 93.44%(57/61),73.77%(45/61)and 52.46%(32/61),which were 88.52%(54/61),55.74%(34/61)and 32.79%(20/61)of the control group.There was no statistically significant difference in 1-year survival rate between the two groups(χ^2=0.899,P>0.05).The survival rate after 3 and 5 years of treatment of the research group was higher than that of the control group,and the difference was statistically significant(χ^2=4.346,4.826;P<0.05).Conclusion The application of CM-NA concurrent chemoradiotherapy in the treatment of esophageal cancer can further improve the therapeutic effect and long-term survival rate under the premise of ensuring safety.